Skip to main content
Log in

Simulation of Human Intravenous and Oral Pharmacokinetics of 21 Diverse Compounds Using Physiologically Based Pharmacokinetic Modelling

Clinical Pharmacokinetics Aims and scope Submit manuscript

Abstract

Background: The importance of predicting human pharmacokinetics during compound selection has been recognized in the pharmaceutical industry. To this end there are many different approaches that are applied.

Methods: In this study we compared the accuracy of physiologically based pharmacokinetic (PBPK) methodologies implemented in GastroPlus™ with the one-compartment approach routinely used at Pfizer for human pharmacokinetic plasma concentration-time profile prediction. Twenty-one Pfizer compounds were selected based on the availability of relevant preclinical and clinical data. Intravenous and oral human simulations were performed for each compound. To understand any mispredictions, simulations were also performed using the observed clearance (CL) value as input into the model.

Results: The simulation results using PBPK were shown to be superior to those obtained via traditional one-compartment analyses. In many cases, this difference was statistically significant. Specifically, the results showed that the PBPK approach was able to accurately predict passive distribution and absorption processes. Some issues and limitations remain with respect to the prediction of CL and active transport processes and these need to be improved to further increase the utility of PBPK modelling. A particular advantage of the PBPK approach is its ability to accurately predict the multiphasic shape of the pharmacokinetic profiles for many of the compounds tested.

Conclusion: The results from this evaluation demonstrate the utility of PBPK methodology for the prediction of human pharmacokinetics. This methodology can be applied at different stages to enhance the understanding of the compounds in a particular chemical series, guide experiments, aid candidate selection and inform clinical trial design.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV
Fig. 1
Table V
Table VI
Fig. 2
Fig. 3
Fig. 4
Table VII
Fig. 5
Fig. 6

References

  1. Dedrick RL. Animal scale-up. J Pharmacokinet Biopharm 1973; 1: 435–61

    PubMed  CAS  Google Scholar 

  2. Boxenbaum H. Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J Pharmacokinet Biopharm 1982; 10: 201–27

    PubMed  CAS  Google Scholar 

  3. Hosea NA, Collard WT, Cole S, et al. Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches. J Clin Pharmacol 2009; 49(5): 513–33

    Article  PubMed  CAS  Google Scholar 

  4. Rowland M, Balant L, Peck C. Physiologically based pharmacokinetics in drug development and regulatory science: a workshop report (Georgetown University, Washington, DC, May 29–30,2002). AAPS PharmSci 2004; 6: E6

    Article  PubMed  Google Scholar 

  5. Nestorov I. Whole body pharmacokinetic models. Clin Pharmacokinet 2003; 42: 883–908

    Article  PubMed  CAS  Google Scholar 

  6. Andersen ME. Development of physiologically based pharmacokinetic and physiologically based pharmacodynamic models for applications in toxicology and risk assessment. Toxicol Letts 1995; 79: 35–44

    Article  CAS  Google Scholar 

  7. Kawai R, Lemaire M, Steimer J-L, et al. Physiologically based pharmacokinetics study on a cyclosporine derivative, SDZ IMM 125. J Pharmacokin Biopharmac 1994; 22(5): 327–65

    CAS  Google Scholar 

  8. Houston JB. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 1994; 47: 1469–79

    Article  PubMed  CAS  Google Scholar 

  9. Howgate EM, Rowland Yeo K, Proctor NJ, et al. Prediction of in vivo drug clearance from in vitro data: I. Impact of interindividual variability. Xeno-biotica 2006; 36(6): 473–97

    CAS  Google Scholar 

  10. Poulin P, Theil FP. A priori prediction of tissue: plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. J Pharm Sci 2000; 89: 16–35

    Article  PubMed  CAS  Google Scholar 

  11. Poulin P, Theil FP. Prediction of pharmacokinetics prior to in vivo studies: 1. Mechanism-based prediction of volume of distribution. J Pharm Sci 2002; 91: 129–56

    Article  PubMed  CAS  Google Scholar 

  12. Poulin P, Schoenlein K, Theil FP. Prediction of adipose tissue: plasma partition coefficients for structurally unrelated drugs. J Pharm Sci 2001; 90: 436–47

    Article  PubMed  CAS  Google Scholar 

  13. Berezhkovskiy LM. Volume of distribution at steady state for a linear pharmacokinetic system with peripheral elimination. J Pharm Sci 2004; 93(6): 1628–40

    Article  PubMed  CAS  Google Scholar 

  14. Rodgers T, Leahy D, Rowland M. Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci 2005; 94: 1259–76

    Article  PubMed  CAS  Google Scholar 

  15. Rodgers T, Rowland M. Physiologically based pharmacokinetic modeling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci 2006; 95(6): 1238–57

    Article  PubMed  CAS  Google Scholar 

  16. Rodgers T, Rowland M. Mechanistic approaches to volume of distribution predictions: understanding the processes. Pharm Res 2007; 24(5): 918–33

    Article  PubMed  CAS  Google Scholar 

  17. Agoram B, Woltosz WS, Bolger MB. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv Drug Deliv Rev 2001; 50 (Suppl. 1): S41–67

    Article  PubMed  CAS  Google Scholar 

  18. Willmann S, Schmitt W, Keldenich J, et al. A physiological model for the estimation of the fraction dose absorbed in humans. J Med Chem 2004; 47: 4022–31

    Article  PubMed  CAS  Google Scholar 

  19. Poulin P, Theil FP. Prediction of pharmacokinetics prior to in vivo studies: II. Generic physiologically based pharmacokinetic models of drug disposition. J Pharm Sci 2002; 91: 1358–70

    Article  PubMed  CAS  Google Scholar 

  20. Theil FP, Guentert TW, Haddad S, et al. Utility of physiologically based pharmacokinetic models to drug development and rational drug discovery candidate selection. Toxicol Lett 2003; 138: 29–49

    Article  PubMed  CAS  Google Scholar 

  21. Jones HM, Parrott N, Jorga K, et al. A novel strategy for physiologically based predictions of human pharmacokinetics. Clin Pharmacokinet 2006; 45(5): 511–42

    Article  PubMed  CAS  Google Scholar 

  22. De Buck SS, Sinha VK, Fenu LA, et al. Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs. Drug Metab Dispos 2007; 35(10): 1766–80

    Article  PubMed  Google Scholar 

  23. Peters SA. Evaluation of a generic physiologically based pharmacokinetic model for lineshape analysis. Clin Pharmacokinet 2008; 47(4): 261–75

    Article  PubMed  CAS  Google Scholar 

  24. Lave T, Parrott N, Grimm HP, et al. Challenges and opportunities with modelling and simulation in drug discovery and drug development. Xenobiotica 2007; 37(10): 1295–310

    Article  PubMed  CAS  Google Scholar 

  25. Leahy DE. Integrating in vitro ADMET data through generic physiologically based pharmacokinetic models. Expert Opin Drug Metab Toxicol 2006; 2(4): 619–28

    Article  PubMed  CAS  Google Scholar 

  26. Jamei M, Marciniak S, Feng K, et al. The Simcyp® population-based ADME simulator. Expert Opin Drug Metab Toxicol 2009; 5(2): 211–23

    Article  PubMed  CAS  Google Scholar 

  27. Brown RP, Delp MD, Lindstedt SL, et al. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health 1997; 13: 407–84

    PubMed  CAS  Google Scholar 

  28. Arundel PH. A multi-compartmental model generally applicable to physiologically-based pharmacokinetics (AstraZeneca, UK) [poster]. 3rd IFAC Symposium: Modelling and Control in Biomedical Systems; 1997 Mar 23–26; Warwick

  29. Yu LX, Amidon GL. A compartmental absorption and transit model for estimating oral drug absorption. Int J Pharm 1999; 186: 119–25

    Article  PubMed  CAS  Google Scholar 

  30. Ito K, Houston JB. Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches. Pharm Res 2005; 22: 103–12

    Article  PubMed  CAS  Google Scholar 

  31. Paine SW, Parker AJ, Gardiner P, et al. Prediction of the pharmacokinetics of atorvastatin, cerivastatin and indomethacin using kinetic models applied to isolated rat hepatocytes. Drug Metab Dispos 2008; 36: 1365–74

    Article  PubMed  CAS  Google Scholar 

  32. Obach RS. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 1999; 27: 1350–9

    PubMed  CAS  Google Scholar 

  33. Brown HS, Griffin M, Houston JB. Evaluation of cryopreserved human hepatocytes as an alternative in vitro system to microsomes for the prediction of metabolic clearance. Drug Metab Disp 2007; 35: 293–301

    Article  CAS  Google Scholar 

  34. McGinnity DF, Soars MG, Urbanowicz RA, et al. Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance. Drug Metab Disp 2004; 32: 1247–53

    Article  CAS  Google Scholar 

  35. Parrott N, Paquereau N, Coassolo P, et al. An evaluation of the utility of physiologically based models of pharmacokinetics in early drug discovery. J Pharm Sci 2005; 94: 2327–43

    Article  PubMed  CAS  Google Scholar 

  36. Jones HM, Parrott N, Ohlenbusch G, et al. Predicting pharmacokinetic food effects using biorelevant solubility media and physiologically based modelling. Clin Pharmacokinet 2006; 45(12): 1213–26

    Article  PubMed  CAS  Google Scholar 

  37. Germani M, Crivori P, Rocchetti M, et al. Evaluation of a basic physiologically based pharmacokinetic model for simulating the first-time-in-animal study. Eur J Pharm Sci 2007; 31: 190–201

    Article  PubMed  CAS  Google Scholar 

  38. De Buck SS, Sinha VK, Fenu LA, et al. The prediction of drug metabolism, tissue distribution, and bioavailability of 50 structurally diverse compounds in rat using mechanism-based absorption, distribution, and metabolism prediction tools. Drug Metab Disp 2007; 35: 649–59

    Article  Google Scholar 

  39. Edginton AN, Theil FP, Schmitt W, et al. Whole body physiologically-based pharmacokinetic models: their use in clinical drug development. Expert Opin Drug Metab Toxicol 2008; 4(9): 1143–52

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The authors would like to acknowledge the vast number of colleagues within Pfizer Worldwide R&D who provided the experimental and clinical data that were used in the analysis. No source of funding was used to assist in the preparation of this study. The authors have no conflicts of interest that are directly relevant to the content of this study.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Hannah M. Jones.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jones, H.M., Gardner, I.B., Collard, W.T. et al. Simulation of Human Intravenous and Oral Pharmacokinetics of 21 Diverse Compounds Using Physiologically Based Pharmacokinetic Modelling. Clin Pharmacokinet 50, 331–347 (2011). https://doi.org/10.2165/11539680-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11539680-000000000-00000

Keywords

Navigation